OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OSR Health (NASDAQ:OSRH) received a Nasdaq Staff Delisting Determination stating that its common stock and warrants are subject to delisting from The Nasdaq Capital Market for not regaining compliance with the minimum $1.00 bid price requirement under Rule 5550(a)(2) within the allotted periods.
The company plans to request a hearing before the Nasdaq Independent Hearings Panel to appeal. According to OSR Health, OSRH traded about 370 million shares on August 17 and 145 million on August 18, 2026, versus a public float of 18.5 million shares, reaching an intraday high of $0.84 on August 18. Because OSR Health has already used its second 180‑day compliance period, its stock (OSRH) and warrants (OSRHW) are scheduled to be suspended from Nasdaq trading at the open on August 26, 2026, with no automatic stay from a timely hearing request. The company cautions there is no assurance the Panel will grant continued listing or reinstatement.
Positive
- Appeal process pursued: OSR Health plans to request a Nasdaq Panel hearing to seek continued listing of OSRH and OSRHW.
- Exceptionally high recent trading volume: About 370 million OSRH shares traded on August 17 and 145 million on August 18, 2026, versus an 18.5 million share public float.
- Share price neared compliance level: OSRH reached an intraday high of $0.84 on August 18, 2026, sixteen cents below Nasdaq’s $1.00 minimum bid threshold.
Negative
- Nasdaq Staff Delisting Determination: Nasdaq notified OSR Health that OSRH common stock and warrants are subject to delisting for failure to meet the minimum bid price rule 5550(a)(2).
- Trading suspension date set: OSRH and OSRHW are scheduled to be suspended from trading on the Nasdaq Capital Market at the open on August 26, 2026.
- Compliance periods exhausted: After an initial 180‑day compliance period to March 4, 2026, and a second to August 31, 2026, OSR Health did not regain minimum bid price compliance.
- Outcome of appeal uncertain: OSR Health notes there is no assurance the Nasdaq Panel will grant continued listing or reinstatement of trading.
Details
Market move: OSRH -13.23% in the Aug 19 session. Nasdaq delisting determination
On Aug 19, the day this news came out, OSRH closed 13.23% below the previous close. Argus tracked a peak move of +37.9% during that session. Argus tracked a trough of -32.4% from its starting point during tracking. Our momentum scanner recorded 130 alerts for this stock that day. Relative volume reached 913.0x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 19 session.
Key Figures
- Minimum bid threshold
- $1.00
- Nasdaq compliance requirement
- August 17 volume
- approximately 370 million shares
- Nasdaq trading volume ranking
- August 18 volume
- approximately 145 million shares
- Nasdaq trading volume ranking
- Public float
- approximately 18.5 million shares
- OSRH public float
- Float turnover
- more than twenty times
- Single-day trading relative to public float
- Intraday high
- $0.84
- August 18, 2026
- Distance from threshold
- sixteen cents
- August 18 intraday high versus $1.00 threshold
- Trading suspension date
- August 26, 2026
- Nasdaq Capital Market opening
Historical Context
-
CEO reaffirmed confidence while discussing Nasdaq compliance and subsidiary opportunities.
-
Company clarified that Nasdaq feedback was preliminary and not an endorsement.
-
Vaximm completed analysis and reported favorable safety and immune-activation findings.
-
Nasdaq reportedly confirmed the CVR program would not mechanically adjust share price.
-
CEO outlined a proposed loyalty program and highlighted VXM01 milestones and assets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
staff delisting determination regulatory
minimum bid price requirement regulatory
public float financial
trading suspension regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications Department notifying the Company that its common stock and warrants are subject to delisting from The Nasdaq Capital Market as a result of the Company's failure to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).
Nasdaq Hearing Request
The Company intends to request a hearing before the Nasdaq Independent Hearings Panel (the "Panel") to appeal the Staff Determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The Company believes it has a compelling case to present to the Panel based on the totality of the circumstances, including OSRH's trading history since listing, the extraordinary market activity observed in OSRH shares on August 17 and 18, 2026 - the two trading days immediately preceding the effective compliance deadline - and the Company's underlying business fundamentals.
On August 17, 2026, OSRH ranked #1 in Most Active Share Volume across all of Nasdaq, with approximately 370 million shares traded. On August 18, 2026, the Company ranked #3, with approximately 145 million shares traded. OSRH's public float is approximately 18.5 million shares meaning the market traded the Company's entire public float more than twenty times over in a single day. The Company's share price reached an intraday high of
The Company believes these market dynamics, and the circumstances that contributed to the compliance shortfall, represent a compelling basis for the Panel's consideration.
"The market spoke with extraordinary conviction on August 17 and 18," said Peter Hwang, Chief Executive Officer of OSR Health. "370 million shares traded in a single day against an 18.5 million share float. We came within sixteen cents of compliance. We are requesting a Panel hearing because we believe the facts support our case, and because our shareholders, who have demonstrated their conviction in this Company so clearly, deserve nothing less than our full effort to fight for continued listing. Whatever the outcome of that process, our commitment to our shareholders does not change."
Important Notice Regarding Trading: Because the Company utilized the second 180-day compliance period under Nasdaq rules, a timely hearing request will not automatically stay the trading suspension. The Company's common stock (OSRH) and warrants (OSRHW) will be suspended from trading on The Nasdaq Capital Market at the opening of business on August 26, 2026. The Company will provide further updates to shareholders regarding the status of its securities as developments warrant. |
About the Staff Determination
The Company was originally notified of its non-compliance with the minimum bid price requirement on September 5, 2025, and was provided an initial 180-calendar-day compliance period through March 4, 2026. On March 5, 2026, the Company received an additional 180-calendar-day compliance period through August 31, 2026. The Staff Determination states that the Company did not regain compliance with the minimum bid price requirement during the applicable compliance period.
The Company intends to request a hearing before the Panel. There can be no assurance that the Panel will grant the Company's request for continued listing or reinstatement of trading.
A copy of this press release is being filed as Exhibit 99.1 to a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on the date hereof.
About OSR Health, Inc.
OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.
Investor Contact
OSR Health, Inc.
Investor Relations
ir@osr-health.com
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Nasdaq Hearings Panel process and anticipated outcome, the Company's intention to request a hearing before the Panel, the anticipated suspension of trading in the Company's securities, the Company's ability to regain or maintain compliance with Nasdaq's listing requirements, and the Company's business prospects and strategic direction. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially, including the outcome of the Nasdaq appeals process, market conditions, and other risks described in the Company's SEC filings. The Company undertakes no obligation to update any forward-looking statement except as required by law.
SOURCE: OSR Health, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.